Skip to main content
. 2021 Jul 26;14:682320. doi: 10.3389/fnmol.2021.682320

FIGURE 4.

FIGURE 4

Lovastatin inhibits the activation of CK2. (A) Kinase activation of CK2. (B) Western blot detecting the levels of CK2α and CK2β. (C,D) Quantitative analysis of CK2α and CK2β levels. (E) Double-immunostaining for p-S129 and CK2α in the SH-SY5Y treated by α-syn PFFs. Bar = 8 μm. (F) Double-immunostaining for p-S129 and CK2β in the SH-SY5Y treated by α-syn PFFs. Bar = 8 μm. (G) Immunostaining showing CK2 inhibitor DMAT decreased the phosphorylation and inclusion. (H) Quantification of p-S129 α-syn after DMAT treatment. (I) Quantification of aggregates after DMAT treatment. (J) Western blot detecting the level of p-S129 α-syn. (K) Quantification of p-S129 α-syn in Western blot. Results are normalized to total α-syn. All data are means ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, ns: not statistically significant, one-way ANOVA with Tukey’s multiple comparisons test. All experiments were performed in triplicate for at least three independent times.